Galectin-3 is a marker of myocardial and vascular fibrosis in Kawasaki disease patients with giant aneurysms

Numano, Fujito; Shimizu, Chisato; Jimenez-Fernandez, Susan; Vejar, Matthew; Oharaseki, Toshiaki; Takahashi, Kei; Salgado, Andrea; Tremoulet, Adriana H.; Gordon, John B.; Burns, Jane C.; Daniels, Lori B.

doi:10.1016/j.ijcard.2015.07.063

Cited by 25 publications

(22 citation statements)

References 35 publications

(50 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Results demonstrate that the degree of myocardial fibrosis can be reflected by elevated serum levels of gal-3 [26]. Plasma Gal-3 levels were all high in patients with pediatric Kawasaki Disease (PKD), young adults late after KD onset (AKD) and aldosterone-producing adenoma (APA) [27,28]. Galectin-3 expression could be increased by PKC activation, which leads to collagen I and fibronection accumulation in cardiomyocytes.…”

Section: Galectin-3mentioning

confidence: 98%

Biomarkers in patients with myocardial fibrosis

Yang

Zheng

et al. 2017

Open Life Sciences

View full text Add to dashboard Cite

show abstract

Section: Galectin-3mentioning

confidence: 98%

Biomarkers in patients with myocardial fibrosis

Yang

Zheng

et al. 2017

Open Life Sciences

View full text Add to dashboard Cite

show abstract

“…Lin et al [ 8 ] found alterations in extracellular matrix biomarkers in Kawasaki disease patients that were suggestive of enhanced collagen synthesis and myocardial fibrosis in adolescents and young adults late after the onset of Kawasaki disease. With blood measurement and tissue autopsy, Numano et al [ 9 ] found Galectin-3 could be a marker of myocardial and vascular fibrosis in Kawasaki disease patients with giant aneurysms. However, myocardial fibrosis was not observed in myocardial tissue of Kawasaki disease with normal coronary arteries [ 9 ].…”

Section: Introductionmentioning

confidence: 99%

“…With blood measurement and tissue autopsy, Numano et al [ 9 ] found Galectin-3 could be a marker of myocardial and vascular fibrosis in Kawasaki disease patients with giant aneurysms. However, myocardial fibrosis was not observed in myocardial tissue of Kawasaki disease with normal coronary arteries [ 9 ].…”

Section: Introductionmentioning

confidence: 99%

Quantitative evaluation of myocardial fibrosis by cardiac integrated backscatter analysis in Kawasaki disease

Xie

Wang

Huang

et al. 2015

Cardiovasc Ultrasound

View full text Add to dashboard Cite

Background: Kawasaki disease is an acute, systemic vasculitis that affects the coronary arteries. However, the relationship between myocardial fibrosis and Kawasaki disease has been completely unknown until now. We aimed to provide quantitative information about myocardial fibrosis using cardiac integrated backscatter in Han race Kawasaki disease patients. Methods: Ninety Kawasaki disease patients and 90 healthy control subjects were recruited. Based on Kawasaki disease status, the patients were categorized into 3 groups: acute, subacute, and convalescence phase. Based on coronary artery status, the Kawasaki disease patients were categorized into 3 groups: without coronary artery lesions, with coronary artery dilation, and with coronary artery aneurysms. All subjects underwent two-dimensional and Doppler examinations to measure clinical echocardiographic parameters. Myocardial fibrosis was detected with calibrated integrated backscatter imaging. Results: Left ventricle systolic functions were normal in both the Kawasaki disease and control participants. The myocardial calibrated integrated backscatter values of the left ventricles of the acute (p < 0.001), subacute (p < 0.001) and convalescence phase (p < 0.001) Kawasaki disease patients were significantly greater than those of the healthy controls. The left ventricle myocardial calibrated integrated backscatter values were significantly smaller in the Kawasaki disease patients without coronary artery lesions than in the Kawasaki disease patients with coronary artery dilations and coronary artery aneurysms in different phases. The left ventricle myocardial calibrated integrated backscatter results were positively correlated with coronary artery status in the acute (r = 0.331, p < 0.001), subacute (r = 0.456, p < 0.001) and convalescence phases (r = 0.407, p < 0.001) of Kawasaki disease. Conclusion: Our findings may suggest that myocardial fibrosis occurs during early episodes of Kawasaki disease given uncertainties that exist regarding correlations of calibrated integrated backscatter and myocardial fibrosis.

show abstract

“…In a study of 81 adult subjects with a history of KD, plasma levels of Gal-3 were elevated only in the 6 subjects with giant coronary artery aneurysms. 75 Immunohistochemical staining of myocardium from autopsies and an explanted heart, decades after acute KD, revealed diffuse myocardial fibrosis, as well as abundant staining of spindleshaped cells with a myofibroblast phenotype. The naturally occurring tetra-peptide, N-acetyl-ser-asp-lys-pro (AcSDKP), has been shown in animal studies to reduce myocardial inflammation, prevent fibrosis mediated by Gal-3, 76,77 and to inhibit epithelial-to-mesenchymal transition in cultured cells.…”

Section: Biomarkers For Detection Of Late CV Fibrosismentioning

confidence: 96%

Adjunctive Testing in the Evaluation of Adults After Kawasaki Disease

Daniels

Burns

2015

Circ J

Self Cite

View full text Add to dashboard Cite

Acute Kawasaki disease (KD) is diagnosed and treated by pediatricians, but decades later, these individuals are presenting to adult cardiologists with a variety of cardiovascular sequelae, including myocardial ischemia and infarction, congestive heart failure secondary to myocardial fibrosis, and claudication because of vascular insufficiency from thrombosed peripheral arteries. There are no clinical trials to guide management, interventions, and medical therapy in this patient population. This review summarizes the emerging information regarding evaluation of the cardiovascular status of adults decades after childhood KD. (Circ J 2015; 79: 2299 -2305

show abstract

Galectin-3 is a marker of myocardial and vascular fibrosis in Kawasaki disease patients with giant aneurysms

Cited by 25 publications

References 35 publications

Biomarkers in patients with myocardial fibrosis

Biomarkers in patients with myocardial fibrosis

Quantitative evaluation of myocardial fibrosis by cardiac integrated backscatter analysis in Kawasaki disease

Adjunctive Testing in the Evaluation of Adults After Kawasaki Disease

Contact Info

Product

Resources

About